Moberg Pharma AB, a Swedish pharmaceutical company, announced that its partner, Menarini Asia-Pacific, has initiated the launch of Kerasal Nail, a topical treatment used to treat nail disease, in China. TV commercials and other advertising started this week in certain parts of southern China.
Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company - includes Italy, China and eight countries in Southeast Asia. In addition to China, launch activities have previously been initiated in Malaysia, Singapore and Hong Kong. Preparations are ongoing in the other markets in the region.
"We are very pleased with the progress and that the launch of Kerasal Nail now has started in China. Kerasal Nail has significant potential in the region. Assuming successful launches, we expect the region to become an important contributor to revenues and earnings from 2015 and onwards," said Peter Wolpert, CEO of Moberg Pharma AB.
Kerasal Nail is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best-selling product in its category in the US. The international launch is under way via a proprietary sales organization in the US and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia.
Kerasal Nail is a prescription-free, over-the-counter product sold under the names Kerasal Nail, Naloc/Nalox and Emtrix. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Kerasal Nail has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments.
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries.
Menarini is the world’s largest Italian biopharmaceutical company with a heritage of over 127 years and nearly 17,000 employees in over 100 countries. In Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region.